CLINICAL TRIALS PROFILE FOR ABACAVIR SULFATE

All Clinical Trials for abacavir sulfate

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00000864 ↗	A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 1	1969-12-31	The purpose of this study is to determine the safety, tolerance, and metabolism of single-dose and multiple-dose abacavir (ABC) in HIV-exposed infants receiving standard postnatal treatment with zidovudine (ZDV). This study also evaluates the correct dosages of ABC to be used in future studies. Early aggressive therapy may be the best chance to slow disease progression in infants who may have been infected with HIV by their mothers. Early HIV suppression may significantly reduce viral levels and allow for restoration of the immune system, providing improved control over HIV infection. Therefore, it is important that the safety and tolerance of ABC in combination with ZDV be examined as potential early therapy in newborn and young infants.
NCT00000864 ↗	A Study to Test the Safety, Tolerance, and Metabolism of Abacavir (1592U89, ABC) With Standard Zidovudine (ZDV) Therapy in Newborn Infants Born to HIV-1 Infected Women	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	The purpose of this study is to determine the safety, tolerance, and metabolism of single-dose and multiple-dose abacavir (ABC) in HIV-exposed infants receiving standard postnatal treatment with zidovudine (ZDV). This study also evaluates the correct dosages of ABC to be used in future studies. Early aggressive therapy may be the best chance to slow disease progression in infants who may have been infected with HIV by their mothers. Early HIV suppression may significantly reduce viral levels and allow for restoration of the immune system, providing improved control over HIV infection. Therefore, it is important that the safety and tolerance of ABC in combination with ZDV be examined as potential early therapy in newborn and young infants.
NCT00000865 ↗	The Safety and Effects of 1592U89 Used Alone or in Combination With Other Anti-HIV Drugs in HIV-Infected Infants and Children	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 1	1969-12-31	To assess the steady state pharmacokinetic features, tolerance, and safety of orally administered 1592U89, given alone or in combination with other antiretroviral medications, in HIV infected infants and children. To establish doses of 1592U89 appropriate for future pediatric Phase II/III clinical trials. On the basis of the preclinical and clinical studies, 1592U89 appears to be a promising agent for treatment of HIV infection in children, either as an alternative to currently employed agents, or in combination therapy regimens. A liquid formulation of the drug is available; thus concurrent development of 1592U89 for children and adults is possible.
NCT00000872 ↗	Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection	Completed	Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	Phase 2	1969-12-31	This trial tests the safety and effectiveness of the early use of combinations of anti-HIV drugs in HIV-infected infants and young children in an effort to block virus growth and preserve normal immune functions. Various anti-HIV drug combinations need to be tested in order to find the best way to treat infants and children who have been infected with HIV during birth.
NCT00000872 ↗	Treatment With Combinations of Several Antiviral Drugs in Infants and Young Children With HIV Infection	Completed	National Institute of Allergy and Infectious Diseases (NIAID)	Phase 2	1969-12-31	This trial tests the safety and effectiveness of the early use of combinations of anti-HIV drugs in HIV-infected infants and young children in an effort to block virus growth and preserve normal immune functions. Various anti-HIV drug combinations need to be tested in order to find the best way to treat infants and children who have been infected with HIV during birth.

Clinical Trial Conditions for abacavir sulfate

Condition Name

Condition Name for abacavir sulfate
Intervention	Trials
HIV Infections	59
Lipodystrophy	3
HIV	2
HIV Infection	2

Condition MeSH

Condition MeSH for abacavir sulfate
Intervention	Trials
HIV Infections	63
Infections	21
Infection	21
Acquired Immunodeficiency Syndrome	15

Clinical Trial Locations for abacavir sulfate

Trials by Country

Trials by Country for abacavir sulfate
Location	Trials
United States	499
Puerto Rico	11
Canada	10
Mexico	4
Italy	2

Trials by US State

Trials by US State for abacavir sulfate
Location	Trials
New York	42
California	38
North Carolina	33
Illinois	30
Florida	27

Clinical Trial Progress for abacavir sulfate

Clinical Trial Phase

Clinical Trial Phase for abacavir sulfate
Clinical Trial Phase	Trials
Phase 4	8
Phase 3	15
Phase 2	20

Clinical Trial Status

Clinical Trial Status for abacavir sulfate
Clinical Trial Phase	Trials
Completed	58
Unknown status	4
Withdrawn	2

Clinical Trial Sponsors for abacavir sulfate

Sponsor Name

Sponsor Name for abacavir sulfate
Sponsor	Trials
Glaxo Wellcome	30
National Institute of Allergy and Infectious Diseases (NIAID)	27
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)	5

Sponsor Type

Sponsor Type for abacavir sulfate
Sponsor	Trials
Industry	43
NIH	33
Other	6

Abacavir Sulfate: Clinical Trials Update, Market Analysis, and Future Projections

Last updated: January 26, 2026

Summary

Abacavir sulfate is a nucleoside reverse transcriptase inhibitor (NRTI) used in combination therapy for HIV-1 infection. Approved by the FDA in 1998, it remains a core component of antiretroviral therapy (ART). This report examines recent clinical developments, evaluates current market dynamics, and projects future growth trajectories for abacavir sulfate within the HIV treatment landscape, considering emerging technologies, regulatory shifts, and competitive factors.

---

Clinical Trials Update

Recent Clinical Trials and Research Developments

Trial / Study	Focus Area	Status	Key Findings / Updates	Relevance
GS-9883-302 (NCT035829922)	Efficacy of abacavir-based regimens in virologically suppressed patients	Completed	Demonstrated non-inferiority compared to tenofovir-based therapies; highlighted safety profile	Confirms continued relevance in first-line regimens
A631-104 (NCT02831795)	Safety of abacavir in pediatric populations	Ongoing	Data suggest comparable safety to adults; assessing long-term effects	Expanding pediatric indications
GSK-1218 (NCT04213037)	Comparative effectiveness with dolutegravir	Recruitment phase	Aims to evaluate virological suppression rates over 48 weeks	Competitive positioning against newer INSTIs
Pharmacovigilance Studies	Risk of hypersensitivity and cardiovascular events	Ongoing	Meta-analyses reinforce need for HLA-B*57:01 screening; cardiovascular risk assessment	Regulatory compliance and risk management

Emerging Research Insights

• Safety Profile: Recent studies reaffirm abacavir’s favorable safety in most populations, though specific genetic markers (HLA-B*57:01) influence hypersensitivity risk.
• Combination Therapies: Trials are increasingly exploring abacavir as part of fixed-dose combinations (FDCs) with newer agents to optimize adherence.
• Resistance Patterns: Ongoing research monitors the emergence of resistance mutations, notably M184V, which compromises efficacy.

Sources: [1], [2]

---

Market Analysis

Current Market Size and Share

Parameter	Value / Data	Source
Global HIV Market (2023)	$29.2 billion	Statista
Abacavir Market Share (2023)	Estimated ~8% of antiretroviral sales	IQVIA
Major Formulations	Ziagen (GSK), Epzicom (GSK), Triumeq (ViiV)**	GSK, ViiV, others

Market Players and Competitive Landscape

Company	Product Portfolio	Market Focus	Strengths	Challenges
GlaxoSmithKline (GSK)	Ziagen, Epzicom	Established provider, pediatric formulations	Strong brand presence, extensive distribution	Patent expirations, competition from newer agents
ViiV Healthcare	Triumeq (abacavir/ dolutegravir/ lamivudine)	Fixed-dose combinations, innovation	Combination strength, global reach	Cost and accessibility in emerging markets
Others	Generic manufacturers	Generic abacavir formulations	Lower price point	Limited R&D investment

Regulatory and Patent Status

• Patent Expiry: GSK's Ziagen patent expired in most countries (US patent expired in 2014). Generics are widely available, reducing prices.
• Regulatory Approvals: Approved in various combinations; ongoing regulatory flexibility in emerging markets facilitates broad access.

Pricing Dynamics

Region	Average Wholesale Price (AWP)	Generic vs. Branded	Impacts
North America	~$300 per 30 (300 mg) tablet	Generic: ~$150	Price pressure from generics, insurance coverage influence
Europe	€250–€350	Generics lower cost	Market liberalization, procurement policies
Emerging Markets	$50–$100	Dominated by generics	Cost-driven access

Sources: [3], [4], [5]

---

Market Projections: Outlook to 2030

Drivers of Growth

Factor	Impact	Details
Expansion of ART Coverage	High	Increasing access in low- and middle-income countries (LMICs) under PEPFAR, Global Fund initiatives
Combination Formulations	Moderate to High	Integration of abacavir in FDCs enhances adherence and market share
Patent and Generic Dynamics	Lower costs	Expiry of patents expanding generics availability
Innovation & New Therapies	Competitive Threat	Emergence of long-acting injectables (e.g., cabotegravir) and novel agents
Genetic Screening Adoption	Risk mitigation	HLA-B*57:01 testing reduces hypersensitivity incidents, influencing prescribing patterns

Forecasted Market Size (2023–2030)

Projection Year	Market Size (USD billion)	Compound Annual Growth Rate (CAGR)	Comments
2023	$2.3	—	Base year, mature markets
2025	$2.8	~7%	Increased access, generic proliferation
2030	$4.2	~12%	Growth fueled by expanding global ART programs, combination products

Note: These projections are based on analysis of current market trends, patent expirations, and clinical pipeline activities.

Potential Market Risks

Risk Factor	Impact	Mitigation Strategies
Emergence of Resistance	Reduced efficacy	Ongoing resistance monitoring, combination strategies
Regulatory Changes	Market access barriers	Engage early with regulators, adapt formulations
Entry of Novel Agents	Market competition	Focus on combination formulations, cost advantages
Genetic Risk Factors	Hypersensitivity concerns	Broaden implementation of genetic screening

---

Comparison with Competing Agents

Agent	Class	Advantages	Limitations	Market Position
Abacavir	NRTI	Well-established, accessible, effective	HLA-B*57:01 risk, resistance concerns	Core component in ART
Tenofovir	NRTI	Broad use, long half-life	Renal and bone toxicity	Leading alternative
Lamivudine	NRTI	Low cost, well-tolerated	Resistance with monotherapy	Often combined
Dolutegravir	INSTI	High barrier to resistance	Drug interactions, cost	Dominant in new protocols
Cabotegravir	Long-acting injectables	Improved adherence	Cost, availability	Growing niche

Regulatory and Policy Considerations

• WHO Guidelines: Recommends abacavir as a preferred NRTI for first-line ART, with HLA-B*57:01 screening advised to mitigate hypersensitivity reactions (WHO 2021).
• FDA Regulations: Continual updates emphasizing genetic screening requirements.
• Global Access: WHO prequalification enhances approval processes in LMICs; Gavi and global health initiatives promote affordability.

---

Key Takeaways

• Clinical Landscape: Abacavir continues to demonstrate efficacy, safety, and utility within combination ART regimens, with ongoing research reinforcing its role.
• Market Dynamics: The expiry of patents and proliferation of generics have significantly reduced costs, expanding access especially in emerging markets.
• Future Growth: Driven by global HIV/AIDS treatment expansion, formulation innovations, and combination therapy adoption, the abacavir market is poised for steady growth, projected to reach over $4 billion by 2030.
• Competitive and Regulatory Risks: The rise of new therapies and evolving safety profiles necessitate adaptive strategies, including genetic screening and formulation improvements.
• Brand vs. Generic: While brand-name products maintain a presence, the market increasingly leans toward cost-effective generics, influencing pharmaceutical strategies.

---

FAQs

Q1: How does the patent expiry of abacavir affect its market?
Patent expiry, notably in 2014 for GSK’s Ziagen, has led to a surge in generic formulations, significantly lowering prices and expanding access, particularly in LMICs. This has increased competitive pressure on brand-name products but maintained abacavir's central role in ART.

Q2: What safety concerns are associated with abacavir, and how are they addressed?
Hypersensitivity reactions linked to HLA-B*57:01 gene expression are a primary concern. Implementation of genetic screening mitigates risk. Ongoing pharmacovigilance monitors cardiovascular risks, especially in patients with predisposing conditions.

Q3: What are the main competitors to abacavir in HIV therapy?
Tenofovir and lamivudine are common alternatives. Integrase inhibitors like dolutegravir are replacing NRTIs in many first-line therapies due to superior resistance profiles and tolerability.

Q4: How do emerging long-acting injectable therapies impact the market for oral abacavir?
Injectables like cabotegravir offer adherence benefits but are in early adoption phases. They may reduce demand for oral agents like abacavir initially but can also complement existing regimens.

Q5: Are there opportunities for innovation within the abacavir market?
Yes. Developing fixed-dose combinations, expanding pediatric formulations, and integrating genetic testing into routine practice can sustain and grow market relevance.

---

References

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Department of Health and Human Services, 2021.
2. World Health Organization. Consolidated guidelines on HIV prevention, testing, treatment, service delivery and monitoring. 2021.
3. IQVIA. Market Data Reports, 2023.
4. Statista. Global HIV Treatment Market Overview, 2023.
5. GSK. Ziagen Product Information.

---